Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | STK3 | Q13188 | 1/20 | 0.52 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 3/20 | 0.42 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674742 | 0.92 | CLK2 (0.52) | CLK2GSK3AGSK3BCSNK2A1STK3 | |
| SCHEMBL881114 | 0.85 | PIK3R1 (0.46) | PIK3R1MTORSMG1PIK3CASYK | |
| SCHEMBL14468924 | 0.77 | CLK2 (0.51) | CLK2GSK3AGSK3BCSNK2A1STK3 | |
| SCHEMBL12091891 | 0.77 | PIK3CA (0.58) | CLK2GSK3AGSK3BCSNK2A1STK3 | |
| SCHEMBL2675087 | 0.76 | PIK3CA (0.53) | PIK3R1MTORSMG1PIK3CAAKT1 | |
| SCHEMBL856429 | 0.75 | CLK2 (0.48) | CLK2GSK3AGSK3BCSNK2A1STK3 | |
| SCHEMBL10327648 | 0.74 | PIK3CA (0.55) | CLK2GSK3AGSK3BCSNK2A1STK3 | |
| SCHEMBL881139 | 0.70 | AIMP2 (0.51) | MTORPIK3CA | |
| SCHEMBL857404 | 0.69 | PIK3CA (0.52) | PIK3R1MTORPIK3CAAKT1 | |
| SCHEMBL881134 | 0.69 | PIK3CA (0.47) | CLK4PIK3CAPIK3CDCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | CLK2 319/4885GSK3A 196/4885GSK3B 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.